[Dosage of presurgical cefazolin in obese and non-obese patients. Does weight matter?]

Autor:	Rodríguez de Castro B; Belén Rodríguez de Castro, Servicio de Farmacia. Hospital Universitario Cabueñes. Los Prados, 395, 33394 Gijón (Asturias). Spain. b.rocas23@gmail.com., Martínez-Múgica Barbosa C, Pampín Sánchez R, Fernández González B, Barbazán Vázquez FJ, Aparicio Carreño C
Jazyk:	Spanish; Castilian
Zdroj:	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2020 Jun; Vol. 33 (3), pp. 207-211. Date of Electronic Publication: 2020 Apr 15.
DOI:	10.37201/req/026.2020
Abstrakt:	Objective: Evaluation of the effectiveness of a standard dose of cefalozin 2 grams for surgical site infection (SSI) prevention in obese patients compared to non-obese patients. There is no still controversy surrounding which is the best dosage of this antibiotic in obese patients for surgical prophylaxis. Methods: Retrospective review of men who received prophylactic cefazolin between January 1st, 2019 and June 30th, 2019 in a traumatology department of a university hospital. Patients were stratified into 2 groups: obese (≥ 100 kg and body mass index (BMI)> 30 kg / m2) and non-obese. Patients without a 90 days follow-up after surgery and/or with an active infection at the time of surgery and/or treated with immunosuppressants were excluded. Demographic data, height, real weight, smoking, diabetes, concomitant use of immunosuppressants, surgery data and presence of infection until day 90 were collected. Results: A total of 57 patients underwent traumatic surgery with prophylactic cefazolin, 26 non-obese and 23 obese, were studied. Both groups presented statistically significant differences in weight, BMI and post-surgery use of cefazolin. No significant differences were observed in the other variables. Two obese (8.7%) and two non-obese (7.7%) patients developed SSIs after 63 days post-surgery on average, following the difference between the groups being statistically non-significant. Conclusions: This study shows that there is no significant difference in SSI with a standard prophylactic dose of two grams of cefazolin between obese and non-obese patients. (©The Author 2020. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu